Ozmosi | BI-44370 Drug Profile

Product Description

For the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00751803)

Mechanisms of Action: CALCA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Boehringer Ingelheim
Company Location: Europe
Company Founding Year: 1885
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Migraine Disorders|Migraine without Aura|Headache|Migraine with Aura

Phase 1: Migraine Disorders|Healthy Volunteers

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT02215759	NCT02215759	P1	Completed	Healthy Volunteers	2009-06-01	2019-03-20	Treatments
NCT00743015	EudraCT 2008-001356-42	P1	Completed	Migraine Disorders	2009-03-01	2019-03-18	Treatments
NCT02215031	NCT02215031	P1	Completed	Healthy Volunteers	2008-11-01	2019-03-20	Treatments
NCT02215772	NCT02215772	P1	Completed	Healthy Volunteers	2008-10-01	2019-03-20	Treatments
NCT02215746	NCT02215746	P1	Completed	Healthy Volunteers	2008-04-01	2019-03-20	Treatments
NCT02217514	NCT02217514	P1	Completed	Healthy Volunteers	2008-03-01	2019-03-20	Treatments
NCT02215018	Four 50 mg Tablets	P1	Completed	Healthy Volunteers	2007-08-01	2019-03-20	Treatments
2008-000079-31	2008-000079-31	P2	Completed	Headache\|Migraine with Aura\|Migraine Disorders\|Migraine without Aura	2009-05-26	2022-03-12	Treatments
NCT00751803	EudraCT No : 2008-000079-31	P2	Completed	Migraine Disorders	2009-05-01	2019-03-18	Treatments

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

BI-44370

Alternative Names: bi-44370, bi 44370, bi44370 Clinical Status: Inactive Latest Update: 2014-11-24 Latest Update Note: Clinical Trial Update